About: Assessment of the Modified CHA2DS2VASc Risk Score in Predicting Mortality in Patients Hospitalized with COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Assessment of the Modified CHA2DS2VASc Risk Score in Predicting Mortality in Patients Hospitalized with COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Assessment of the Modified CHA2DS2VASc Risk Score in Predicting Mortality in Patients Hospitalized with COVID-19
Creator	Cetinkal, Gokhan Demir, Tolga Keskin, Kudret Kilci, Hakan Kilickesmez, Kadriye Kocas, Balaban Kocas, Betul Ozcan, Nur Ozcan, Safiye Ser, Selim Verdi, Yildiz Zeren, Mustafa
source	Elsevier; PMC
abstract	Since the modified CHA2DS2VASC (M-CHA2DS2VASc) risk score (RS) includes the prognostic risk factors for COVID-19; we assumed that it might predict in-hospital mortality and identify high risk patients at an earlier stage compared with troponin increase and neutrophil-lymphocyte ratio (NLR). We aimed to investigate whether M-CHA2DS2VASC RS is an independent predictor of mortality in patients hospitalized with COVID-19 and to compare its discriminative ability with troponin increase and NLR in terms of predicting mortality. 694 patients were retrospectively analyzed and divided into three groups according to M-CHA2DS2VASC RS which was simply created by changing gender criteria of the CHA2DS2VASC RS from female to male (Group 1, score 0-1 (n= 289); group 2, score 2-3 (n=231) and group 3, score ≥4 (n=174)). Adverse clinical events were defined as in-hospital mortality, admission to intensive care unit, need for high-flow oxygen and/or intubation. As the M-CHA2DS2VASC RS increased, adverse clinical outcomes were also significantly increased (Group 1, 3.8%; group 2, 12.6%; group 3, 20.8%; p<0.001 for in-hospital mortality). The multivariate logistic regression analysis showed that M-CHA2DS2VASC RS, troponin increase and NLR were independent predictors of in-hospital mortality (p=0.005, odds ratio 1.29 per scale for M-CHA2DS2VASC RS). In ROC analysis, comparative discriminative ability of M-CHA2DS2VASC RS was superior to CHA2DS2VASC RS score. Area under the curve (AUC) values for in-hospital mortality were 0.70 and 0.64 respectively. (AUC(M-CHA2DS2-VASc) vs. AUC(CHA2DS2-VASc) z test=3.56, p 0.0004) In conclusion, admission M-CHA2DS2VASc RS may be a useful tool to predict in-hospital mortality in patients with COVID-19.
has issue date	2020-08-28(xsd:dateTime)
bibo:doi	10.1016/j.amjcard.2020.08.040
has license	no-cc
sha1sum (hex)	e9063f20bd940529d0f0343abd108f5746b9eca8
schema:url	https://doi.org/10.1016/j.amjcard.2020.08.040
resource representing a document's title	Assessment of the Modified CHA2DS2VASc Risk Score in Predicting Mortality in Patients Hospitalized with COVID-19
has PubMed Central identifier	PMC7453224
schema:publication	Am J Cardiol
resource representing a document's body	covid:e9063f20bd940529d0f0343abd108f5746b9eca8#body_text
is schema:about of	named entity 'high risk' named entity 'troponin' named entity 'group 3' named entity 'intubation' named entity 'modified' named entity 'The' named entity 'investigate' named entity 'INDEPENDENT' named entity 'MAY BE A' named entity 'RISK SCORE' named entity 'HIGH RISK' named entity 'ACCORDING' named entity 'ANALYZED' named entity '3D3' named entity 'INDEPENDENT PREDICTORS' named entity 'ADMISSION TO INTENSIVE CARE UNIT' named entity 'TO INVESTIGATE' named entity 'ODDS RATIO' named entity 'ROC ANALYSIS' named entity 'IDENTIFY' named entity '2-3' named entity '0.64' named entity 'FLOW' named entity 'SCALE' covid:arg/e9063f20bd940529d0f0343abd108f5746b9eca8 named entity 'CHA2DS2-VASc' named entity 'Adverse' named entity 'mortality' named entity 'AUC' named entity 'NLR' named entity 'gender' named entity 'identify' named entity 'troponin' named entity 'COPD' named entity 'mortality' named entity 'troponin' named entity 'divided' named entity 'female' named entity 'patients' named entity 'male' named entity 'COVID-19' named entity 'COVID-19' named entity 'AUC' named entity 'oxygen' named entity 'intensive care unit' named entity 'prognostic' named entity 'intubation' named entity 'AUC' named entity 'COVID-19' named entity 'intubation' named entity 'transient ischemic attack' named entity 'stroke' named entity 'cerebrovascular disease' named entity 'ferritin' named entity 'complete blood count' named entity 'COVID-19' named entity 'respiratory rate' named entity 'respiratory failure' named entity 'diabetes mellitus' named entity 'cardiovascular disease' named entity 'oxygen' named entity 'congestive heart failure' named entity 'clinical outcomes' named entity 'malignancies' named entity 'COVID-19' named entity 'blood test' named entity 'blood oxygen saturation' named entity 'Turkey' named entity 'COVID-19' named entity 'attending physician' named entity 'radiographic' named entity 'final analysis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software